Lixisenatide is a new GLP‐1 receptor agonist that shows neuroprotective effects in animal models of AD (Cai et al., 2017, 2018; McClean & Hoelscher, 2014a, 2014b). The gene discussed is GLP1R; the disease is Alzheimer disease.